MedPath

Durham University

🇬🇧United Kingdom
Ownership
-
Established
1832-01-01
Employees
4.2K
Market Cap
-
Website
https://dur.ac.uk

Clinical Trials

12

Active:3
Completed:5

Trial Phases

1 Phases

Not Applicable:9

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Not Applicable
9 (100.0%)

Visual Perception Difficulties After Stroke

Recruiting
Conditions
Stroke
Visual Perception
First Posted Date
2023-08-08
Last Posted Date
2024-08-06
Lead Sponsor
Durham University
Target Recruit Count
200
Registration Number
NCT05981482
Locations
🇬🇧

Abingdon Community Hospital, Abingdon, United Kingdom

🇬🇧

Bishop Auckland Hospital, Bishop Auckland, United Kingdom

🇬🇧

Queen Elizabeth Hospital, Gateshead, United Kingdom

Sex Differences in Muscle Damage Following Resistance Exercise at Low or High Intensity

Not Applicable
Suspended
Conditions
Muscle Damage
First Posted Date
2021-11-08
Last Posted Date
2021-11-16
Lead Sponsor
Durham University
Target Recruit Count
40
Registration Number
NCT05111054
Locations
🇬🇧

Durham University, The Graham Sports Centre, Durham, County Durham, United Kingdom

Sex Differences in Muscle Damage Following Resistance Exercise With or Without Milk Protein Ingestion

Not Applicable
Conditions
Muscle Damage
First Posted Date
2021-08-02
Last Posted Date
2021-10-27
Lead Sponsor
Durham University
Target Recruit Count
40
Registration Number
NCT04986150
Locations
🇬🇧

Durham University, Sports and Wellbeing Park, Durham, United Kingdom

Terahertz Metamaterials for Tumour Marker Concentration Identification

Suspended
Conditions
Malignant Tumour
First Posted Date
2019-10-14
Last Posted Date
2023-11-01
Lead Sponsor
Durham University
Target Recruit Count
90
Registration Number
NCT04125524
Locations
🇬🇧

Department of Engineering Durham University, Durham, United Kingdom

News

Magnitude Biosciences Secures £700K to Advance High-Throughput Drug Discovery Platform

Durham University spin-out Magnitude Biosciences raised £700,000 through investors and grants to develop its WormGazer high-throughput screening platform for age-related conditions and difficult-to-treat diseases.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.